# US 2022/0033419 A1 · Furo[3,4-b]pyrrole-containing btk inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033419 A1
- Document ID: US20220033419A1
- Status: Published application
- Kind: A1
- Application number: 17/276,025
- Filed: 2019-09-12
- Published: 2022-02-03
- Earliest claimed: 2018-09-14
- Assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Applicants: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Inventors: Yinsheng Zhang; Hongjiang Xu; Jing Ren; Qinglin Wang; Zheyang Wu; Chao Jin; Wei Shi; Xiaojin Wang; Xiangyi He; Xiayun Chang; Jie WANG; Tianxiao Zhao
- Web page: https://patentgrep.com/patent/US20220033419A1

## CPC

- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application belongs to the field of pharmaceutical chemistry, and relates to a furo[3,4-b]pyrrole-containing BTK inhibitor, and in particular, to a compound of formula (I), a stereisomer or pharmacologically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and use thereof in treating BTK-related diseases.

## Claims

### Claim 1

A compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof,
wherein,
ring B is selected from the group consisting of 5-10 membered heteroaryl and C6-10 aryl;
R1 is independently selected from the group consisting of halogen, —OH, —NH2, cyano, C1-6 alkyl and C1-6 alkoxy, wherein C1-6 alkyl or C1-6 alkoxy is optionally substituted with halogen;
m is 0, 1, 2, 3 or 4;
L is selected from the group consisting of —C(O)NH—, —NHC(O)—, —O—, —NH—, —S—, —C(O)O—, —OC(O)—, —S(O)2O— and —OS(O)2—;
R2 is independently selected from the group consisting of halogen, —OH, —NH2, cyano, C1-6 alkyl and C1-6 alkoxy, wherein C1-6 alkyl or C1-6 alkoxy is optionally substituted with halogen;
n is 0, 1, 2, 3 or 4;
R3 is selected from the group consisting of H, RaC(O)—, RaS(O)2— and Ra—;
R5 is independently selected from the group consisting of halogen, —OH, —NH2, cyano, C1-6 alkyl and C1-6 alkoxy;
p is 0, 1, 2 or 3;
R4 is selected from the group consisting of hydrogen, RaS(O)2—, (RaO)2P(O)— and RaC(O)—;
wherein Ra is independently selected from the group consisting of C2-6 alkynyl, C2-6 alkenyl, C1-6 alkyl, C3-6 cycloalkyl, (C1-6 alkyl)NH—, (C1-6 alkyl)2N—, 3- to 6-membered heterocycloalkyl, 5- to 10-membered heteroaryl and C6-10 aryl, wherein Ra is optionally substituted with (C1-6 alkyl)2N—, (C1-6 alkyl)NH—, hydroxy, amino, halogen or cyano.

### Claim 2 (depends on 1)

The compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof according to claim 1, wherein ring B is selected from the group consisting of 5- to 6-membered heteroaryl and phenyl.

### Claim 3 (depends on 1)

The compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof according to claim 1, wherein R1 is independently selected from the group consisting of halogen, C1-3 alkyl and C1-3 alkoxy, wherein C1-3 alkyl or C1-3 alkoxy is optionally substituted with halogen.

### Claim 4 (depends on 1)

The compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof according to claim 1, wherein m is 0, 1 or 2.

### Claim 5 (depends on 1)

The compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof according to claim 1, wherein L is selected from the group consisting of —C(O)NH—, —NHC(O)—, —C(O)O— and —OC(O)—.

### Claim 6 (depends on 1)

The compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof according to claim 1, wherein R2 is independently selected from the group consisting of halogen, —OH, —NH2, C1-3 alkyl and C1-3 alkoxy.

### Claim 7 (depends on 1)

The compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof according to claim 1, wherein n is 0, 1 or 2.

### Claim 8 (depends on 1)

The compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof according to claim 1, wherein R3 is selected from the group consisting of H, RaC(O)— and RaS(O)2—.

### Claim 9 (depends on 1)

The compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof according claim 1, wherein Ra is independently selected from the group consisting of C2-6 alkynyl, C2-6 alkenyl, C1-6 alkyl, C3-6 cycloalkyl, (C1-6 alkyl)NH—, (C1-6 alkyl)2N—, 3- to 6-membered heterocycloalkyl, 5- to 10-membered heteroaryl and C6-10 aryl, wherein Ra is optionally substituted with (C1-3 alkyl)2N—, (C1-3 alkyl)NH—, hydroxy or amino.

### Claim 10 (depends on 1)

The compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof according to claim 1, wherein R5 is independently selected from the group consisting of F, —OH, —NH2, methyl and methoxy, and p is 0, 1 or 2.

### Claim 11 (depends on 1)

The compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof according to claim 1, wherein R4 is selected from the group consisting of hydrogen, C3-6 cycloalkyl-S(O)2— and (C1-6 alkyl-O)2P(O)—.

### Claim 12 (depends on 1)

The compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof according to claim 1, wherein the compound of formula (I) is selected from the group consisting of a compound of formula (II) and a compound of formula (III),

### Claim 13 (depends on 1)

The compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof according to claim 1, selected from the following compounds, a stereoisomer thereof or a pharmaceutically acceptable salt thereof:

### Claim 14 (depends on 1)

A pharmaceutical composition comprising the compound, a stereoisomer thereof or a pharmaceutically acceptable salt thereof according to claim 1.

### Claim 15 (depends on 1)

A method for treating a BTK-related disease in a mammal, comprising administering to the mammal in need of such treatment a therapeutically effective amount of the compound, a stereoisomer thereof or a pharmaceutically acceptable salt thereof according to claim 1.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the BTK-related disease is selected from the group consisting of autoimmune diseases, inflammatory diseases and cancer; or the BTK-related disease is diffuse large B-cell lymphoma.

### Claim 17 (depends on 2)

The compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof according to claim 2, wherein ring B is pyridinyl.

### Claim 18 (depends on 3)

The compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof according to claim 3, wherein R1 is trifluoromethyl.

### Claim 19 (depends on 9)

The compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof according to claim 9, wherein Ra is independently selected from the group consisting of propynyl, C2-3 alkenyl, methyl, cyclopropyl, cyclobutyl, CH3NH—, (CH3)2CHNH— and (CH3)2N—, wherein methyl, C2-3 alkenyl and cyclopropyl are optionally substituted with (CH3)2N—, hydroxy or amino.

### Claim 20 (depends on 1)

The compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof according to claim 1, wherein R4 is selected from the group consisting of hydrogen, cyclopropyl-S(O)2— and (CH3O)2—P(O)—.
